Please ensure Javascript is enabled for purposes of website accessibility

Why Iveric Bio Is Skyrocketing 24% Today

By Todd Campbell – Jun 18, 2020 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An upsized public offering has investors increasingly confident about its prospects.

What happened

After reporting 18-month results from a phase 3 trial evaluating the drug Zimura in geographic atrophy on June 15, Iveric Bio (ISEE 5.61%) is tapping investors for more cash, increasing the likelihood its cash stockpile can last it through Zimura's clinical-stage development.

So what

In an update last week, Iveric Bio announced that Zimura's use reduced the progression of GA versus placebo. At the 18-month mark, patients receiving the 2 mg dose of Zimura had a 28% relative benefit when compared to the control arm of the study. 

A pair of glasses on a ledge overlooking a city.

Image source: Getty Images.

To confirm results from this trial, the biotech company expects to begin enrolling patients in a second phase 3 study this month. If this new trial also shows a benefit versus placebo after 12 months, management intends to file for Food and Drug Administration (FDA) approval. Since this trial will enroll hundreds of patients, management announced plans to raise $50 million yesterday via a stock offering. Today Iveric Bio announced a much larger offering that could generate gross proceeds of $143.9 million if everything goes according to plan.

Specifically, Iveric Bio has priced 24,535,720 common shares at $4.10 per share, and for certain investors it's also offering prefunded warrants to purchase 1,914,280 shares at $4.099 per share. Additionally, it's selling 8,649,453 shares to affiliates of Vivo Capital and Samsara BioCapital at $4.10 per share in a private placement. Brokers can also buy 3,967,500 shares to cover overallotments associated with the public offering, if necessary.

Management didn't say how much it will net from these deals after fees, but the gross proceeds suggest the company is significantly extending its cash runway. Previously, Iveric Bio said the $108.4 million in cash and equivalents on its balance sheet at the end of March was enough to last it into early 2022.

Now what

Geographic atrophy can lead to blindness, and currently there aren't any drugs on the market that specifically target this condition. Iveric Bio estimates its target market is 159,000 patients per year in the U.S. and up to 5 million patients globally, so Zimura could generate significant sales if this upcoming study pans out. Although there's no guarantee of success, the fact that it was able to upsize its offering suggests investors are optimistic. 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

IVERIC bio, Inc. Stock Quote
IVERIC bio, Inc.
ISEE
$16.38 (5.61%) $0.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.